Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies. (Q38212951)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24842496%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

title

Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24842496%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

author name string

Toby A Eyre

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24842496%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Kate Cwynarski

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24842496%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

language of work or name

English

0 references

publication date

19 May 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24842496%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Haematology

18 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24842496%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

volume

166

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24842496%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24842496%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

page(s)

336-351

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24842496%20AND%20SRC:MED&resulttype=core&format=json

Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action

18 March 2020

cites work

1 reference

Rapamycin shows anticancer activity in primary chronic lymphocytic leukemia cells in vitro, as single agent and in drug combination

21 January 2018

1 reference

Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors

21 January 2018

1 reference

Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation

21 January 2018

1 reference

Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group

21 January 2018

1 reference

Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study

21 January 2018

1 reference

Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma

21 January 2018

1 reference

The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma

21 January 2018

1 reference

Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma

21 January 2018

1 reference

Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin

21 January 2018

1 reference

mTORC1- and mTORC2-interacting proteins keep their multifunctional partners focused.

21 January 2018

1 reference

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

21 January 2018

1 reference

The phosphoinositide 3-kinase pathway

21 January 2018

1 reference

Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells

21 January 2018

1 reference

Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia

21 January 2018

1 reference

Targeting the mTOR signaling network in cancer.

21 January 2018

1 reference

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity

21 January 2018

1 reference

Inhibition of the mammalian target of rapamycin (mTOR) in a case of refractory primary cutaneous anaplastic large cell lymphoma

21 January 2018

1 reference

NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy.

21 January 2018

1 reference

Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma

21 January 2018

1 reference

A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL.

21 January 2018

1 reference

Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma

21 January 2018

1 reference

Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR.

21 January 2018

1 reference

21 January 2018

mTOR and cancer therapy

1 reference

mTOR and cancer: many loops in one pathway.

21 January 2018

1 reference

Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.

21 January 2018

1 reference

The coordinate regulation of the p53 and mTOR pathways in cells

21 January 2018

1 reference

Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression

21 January 2018

1 reference

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma

21 January 2018

1 reference

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

21 January 2018

1 reference

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

21 January 2018

1 reference

Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia

21 January 2018

1 reference

Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism

21 January 2018

1 reference

Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma

21 January 2018

1 reference

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma

21 January 2018

1 reference

Global and specific translational control by rapamycin in T cells uncovered by microarrays and proteomics

21 January 2018

1 reference

Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2

21 January 2018

1 reference

Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies

21 January 2018

1 reference

Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma

21 January 2018

1 reference

Upstream and downstream of mTOR

21 January 2018

1 reference

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eIF-4E)/RAF pathway and

21 January 2018

1 reference

mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events

21 January 2018

1 reference

The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling.

21 January 2018

1 reference

The TSC1-TSC2 complex is required for proper activation of mTOR complex 2

21 January 2018

1 reference

Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors

21 January 2018

1 reference

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

21 January 2018

1 reference

Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia

21 January 2018

1 reference

Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.

21 January 2018

1 reference

A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas.

21 January 2018

1 reference

Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia

21 January 2018

1 reference

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

21 January 2018

1 reference

The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells

21 January 2018

1 reference

ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells

21 January 2018

1 reference

Treatment of older patients with mantle-cell lymphoma.

21 January 2018

1 reference

The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia

21 January 2018

1 reference

Syk-dependent mTOR activation in follicular lymphoma cells.

21 January 2018

1 reference

Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer.

21 January 2018

1 reference

Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control

21 January 2018

1 reference

Defining the role of TORC1/2 in multiple myeloma

21 January 2018

1 reference

Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1

21 January 2018

1 reference

AKT/PKB signaling: navigating downstream

21 January 2018

1 reference

Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease--a combined tissue microarray, in vitro and in vivo study

21 January 2018

1 reference

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors

21 January 2018

1 reference

Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.

21 January 2018

1 reference

IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes.

21 January 2018

1 reference

Retracted: Simultaneous Inhibition of mTOR-Containing Complex 1 (mTORC1) and MNK Induces Apoptosis of Cutaneous T-Cell Lymphoma (CTCL) Cells

21 January 2018

1 reference

Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.

21 January 2018

1 reference

Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs

21 January 2018

1 reference

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma

21 January 2018

1 reference

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma

21 January 2018

1 reference

Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals

21 January 2018

1 reference

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma

21 January 2018

1 reference

DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival

21 January 2018

1 reference

Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.

21 January 2018

1 reference

Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014.

21 January 2018

1 reference

A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

PI3-kinase and TOR: PIKTORing cell growth

21 January 2018

1 reference

Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia.

21 January 2018

1 reference

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

21 January 2018

1 reference

Eukaryotic Translation Initiation Factor 4E Regulates Expression of Cyclin D1 at Transcriptional and Post-transcriptional Levels

21 January 2018

1 reference

Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma

21 January 2018

1 reference

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

21 January 2018

1 reference

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

21 January 2018

1 reference

PKB/AKT: functional insights from genetic models

21 January 2018

1 reference

TOR, a central controller of cell growth

21 January 2018

1 reference

Regulation of the mTOR Complex 1 Pathway by Nutrients, Growth Factors, and Stress

21 January 2018

1 reference

The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity

21 January 2018

1 reference

Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells

21 January 2018

1 reference

Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium

21 January 2018

1 reference

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy

21 January 2018

1 reference

The Pim kinases: new targets for drug development

21 January 2018

1 reference

mTOR and cancer: reason for dancing at the crossroads?

21 January 2018

1 reference

Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma

21 January 2018

1 reference

Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle

21 January 2018

1 reference

Expression of the eukaryotic translation initiation factors 4E and 2alpha in non-Hodgkin's lymphomas

21 January 2018

1 reference

Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation

21 January 2018

1 reference

Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.

21 January 2018

1 reference

The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia.

21 January 2018

1 reference

A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse la

21 January 2018

1 reference

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

21 January 2018

1 reference

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

21 January 2018

1 reference

Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab

21 January 2018

1 reference

Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma

21 January 2018

1 reference

Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.

21 January 2018

1 reference

Concurrent inhibition of PI3-kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1.

21 January 2018

1 reference

Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment

21 January 2018

1 reference

PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR

21 January 2018

1 reference